4DMedical Ltd.ASX: 4DX

FY2025 Full year results

· Issued by 4DMedical Ltd.

Filed with ASX · · 6 pages · English

Summary by 6ix AI

The company reported a substantial increase in operating revenue, driven by growth in its Software-as-a-Service offerings and strategic investments. The filing outlines the progress of its CT:VQ™ software, which is undergoing FDA review and aims to revolutionize lung imaging without contrast agents. Overall, the report emphasizes the company's commitment to expanding its global footprint and improving respiratory diagnostics through innovative technology.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

4DMedical Ltd. on 6ix

Story so far

Earlier from 4DMedical

Later from 4DMedical

All 4DMedical news releases